ARTICLE SUMMARY:
To realize its goal of accessing external innovation, LEO Pharma faces several challenges; it’s focused solely on dermatology, and as a mid-sized specialty pharma, it has to be choosy about the acquisitions it makes. It’s addressing those challenges through its Cambridge-based LEO Science & Tech Hub, which aims to be the partner of choice for medtech innovators.
Pharmaceutical and medical device companies are aware that beyond a certain relatively small size, their bulk, culture, and the dictates of their commercial mandate stymie innovation. For the past two decades, most of their innovation has tended to come from the acquisition of start-ups that can operate more nimbly to bring novel science and inventions forward.
